State Street’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-39,530
Closed -$23.3K – 4315
2024
Q4
$23.3K Hold
39,530
– – ﹤0.01% 4222
2024
Q3
$31.2K Hold
39,530
– – ﹤0.01% 4167
2024
Q2
$50.2K Hold
39,530
– – ﹤0.01% 4139
2024
Q1
$54.9K Buy
39,530
+5
+0% +$8 ﹤0.01% 4142
2023
Q4
$62.8K Buy
39,525
+7,325
+23% +$9.34K ﹤0.01% 4154
2023
Q3
$45.7K Buy
32,200
+3,900
+14% +$6K ﹤0.01% 4309
2023
Q2
$45K Hold
28,300
– – ﹤0.01% 4444
2023
Q1
$23.8K Hold
28,300
– – ﹤0.01% 4657
2022
Q4
$40.2K Hold
28,300
– – ﹤0.01% 4608
2022
Q3
$55K Hold
28,300
– – ﹤0.01% 4637
2022
Q2
$57K Hold
28,300
– – ﹤0.01% 4697
2022
Q1
$90K Hold
28,300
– – ﹤0.01% 4673
2021
Q4
$106K Sell
28,300
-1,300
-4% -$7.36K ﹤0.01% 4566
2021
Q3
$200K Sell
29,600
-15,100
-34% -$118K ﹤0.01% 4360
2021
Q2
$457K Buy
+44,700
New +$374K ﹤0.01% 3890

State Street's CYTH Position: Q1 2025 in Review

State Street sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 39,530 shares — an estimated $23.3K sold.

State Street first reported a position in CYTH in Q2 2021 and held it in 15 quarters. The position peaked at $457K in Q2 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

  • State Street reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • State Street sold 39,530 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $23.3K.
  • State Street first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
  • State Street's Cyclo Therapeutics, Inc. Common Stock position peaked at $457K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.